38 results about "N gonorrhoeae" patented technology

The invention relates to lactobacillus gasseri FMTA1125B with the effect of preventing, relieving or treating vaginitis and application of the lactobacillus gasseri FMTA1125B. The lactobacillus gasseri FMTA1125B is classified and named as lactobacillus gasseri, and the preservation number of the lactobacillus gasseri FMTA1125B is CGMCC No.34292. The lactobacillus gasseri FMTA1125B has the effects of preventing, relieving or treating vaginitis and the application of the lactobacillus gasseri FMTA1125B. The bacterium can produce beneficial components such as lactic acid, gamma-aminobutyric acid and hydrogen peroxide through metabolism so as to regulate the genital tract environment and improve the health degree; and the traditional Chinese medicine composition has relatively good bacteriostasis and sterilization effects on common vaginal pathogenic bacteria such as escherichia coli, staphylococcus aureus, gardnerella vaginalis, candida albicans, neisseria gonorrhoeae and the like. Therefore, the lactobacillus gasseri FMTA1125B strain can be used for preparing a preparation with the effect of improving related genital tract diseases such as vaginitis.

The invention discloses a primer combination for identifying six genital tract pathogens and detecting drug resistance genes, a kit and application, the primer combination comprises a primer combination for identifying chlamydia trachomatis, mycoplasma genitalium, ureaplasma urealyticum, mycoplasma hominis, neisseria gonorrhoeae and trichomonas vaginalis and detecting the drug resistance genes of the six genital tract pathogens, and nucleotide sequences are shown as SEQ ID NO.1-SEQ ID NO.50. Microorganisms and related drug-resistant genes in a detection range are identified by utilizing a multiple PCR targeted three-generation sequencing method, the specificity is good, the sensitivity is high, the detection technology has important clinical significance when being applied to identification of genital tract infection pathogens, and compared with a traditional detection method, the detection flux, the coverage range and the sensitivity are higher, and detection is stable; compared with pathogenic microorganism metagenome (mNGS) detection, the method has the advantages that the detection cost is lower, and the detection sensitivity on drug-resistant genes and drug-resistant gene mutation is higher.

The invention relates to lactobacillus gasseri FMTA1121E with an effect of regulating a vaginal micro-ecological environment and application of the lactobacillus gasseri FMTA1121E. The lactobacillus gasseri FMTA1121E is classified and named as lactobacillus gasseri, and the preservation number of the lactobacillus gasseri FMTA1121E is CGMCC No.34962. The lactobacillus gasseri FMTA1121E can be metabolized to generate beneficial components such as lactic acid, gamma-aminobutyric acid and hydrogen peroxide so as to regulate the genital tract environment and improve the health degree; and the bacillus subtilis has excellent bacteriostasis and sterilization effects on various common vaginal pathogenic bacteria such as escherichia coli, staphylococcus aureus, gardnerella vaginalis, candida albicans, neisseria gonorrhoeae and the like. Therefore, the lactobacillus gasseri FMTA1121E strain can be applied to preparation of preparations for preventing and treating related genital tract diseases such as vaginitis.

The invention provides a primer group, a kit and a method for simultaneously detecting 11 microorganisms and diagnosing chronic endometritis intrauterine infection. The primer group is used for detecting the existence of 11 chronic endometritis pathogens: chlamydia trachomatis, enterococcus faecalis, escherichia coli, trichomonas vaginalis, klebsiella pneumoniae, mycoplasma hominis, neisseria gonorrhoeae, staphylococcus, streptococcus, reproductive mycoplasma and ureaplasma urealyticum. The primer group is used for performing multiple joint detection on chronic endometritis related pathogens, has high specificity and sensitivity, and is adaptive to an endometrial tissue sample. The invention provides a method for simultaneously detecting 11 microorganisms for diagnosing chronic endometritis intrauterine infection, which comprises the following steps of: collecting an endometrial sample by adopting a disposable sterile endometrial sampler, detecting 11 microorganisms in the endometrial sample by adopting a multiplex PCR (Polymerase Chain Reaction) technology, and accurately detecting the intrauterine microbial infection condition. Meanwhile, more accurate technical support is provided for clinically identifying whether pathogenic bacteria causing chronic endometritis exist or not, and clinical doctors can comprehensively consider medication guidance conveniently.

Neisseria gonorrhoeae is one of the most common bacterial sexually transmitted infections (STI). Diagnosis depends on standard nucleic acid amplification testing (NAAT), which is impracticable in most low-resource settings, where the prevalence of this STI is highest. Consequently, such areas utilize syndromic management, which misses a high proportion of cases and leads to antibiotic overuse, contributing to the troubling rise of resistance to the commonly prescribed ciprofloxacin, cefixime and ceftriaxone antibiotics for the treatment of N. gonorrhoeae infections. A specific, highly sensitive and cost-effective lateral flow assay is disclosed that utilizes CRISPR-Cas orthologs, multiplex SHERLOCK technology and isothermal amplification via recombinase polymerase amplification (RPA) for the rapid detection of antibiotic resistance to ciprofloxacin, cefixime and / or ceftriaxone at the point of care. This approach has the potential to increase treatment efficacy in the field and mitigate the spread of antibiotic resistance.

This invention provides bfrA Single gene knockout or bfrA Genes and bfrB Double gene knockout of Neisseria gonorrhoeae and its applications involve the field of biotechnology. Research has found that... bfrA Single gene knockout and bfrA and bfrB Double gene knockout of Neisseria gonorrhoeae resulted in increased formation of vesicles on the outer membrane, disruption of the cell wall and cell membrane, reduced adhesion and invasion abilities, decreased bacterial activity, decreased ATP levels, and weakened ability to infect mice. Therefore, knocking out Neisseria gonorrhoeae... bfrA Gene or bfrA and bfrB The dual-gene assay can be used to prepare products for the production of gonococcal outer membrane vesicles and to construct low-pathogenic gonococcal models.

This invention relates, inter alia, to an immunogenic fragment of a Neisserial Heparin Binding Antigen (NHBA) protein of Neisseria gonorrhoeae (SEQ ID NO: 1) for the prevention and treatment of Neisseria gonorrhoeae or gonococcal- or meningococcal-associated diseases and conditions. In some embodiments, the immunogenic fragment corresponds to a C-terminal fragment of the protein (SEQ ID NO: 2).

The present invention relates to compositions and methods for preventing and / or treating bacterial disease (e.g., disease caused by Neisseria spp. such as Neisseria gonorrhoeae or Neisseria meningitidis). In particular, the present invention provides compositions comprising an effective amount of a nucleic acid, wherein such compositions are capable of killing or inhibiting the growth of a Neisseria spp and sensitizing Neisseria spp to antibiotic treatment.

The invention belongs to the technical field of biological medicines, and particularly relates to a neisseria gonorrhoeae chromogenic culture medium. According to the chromogenic culture medium, a supplement and a composite bacteriostatic agent are additionally added into a gonococcus culture medium, and the supplement is prepared from 50-200 ml / L of horse serum, 1-20 mg / L of hemin chloride, 25-250 mg / L of L-proline beta-naphthylamide hydrochloride, 500-5000 mg / L of 1, 3, 4-trimethyl-1, 3-pentanediol monoisobutyrate, 10-20 mg / L of sodium chloride, 10-20 mg / L of sodium chloride, 10-20 mg / L of sodium chloride, 10-20 mg / L of sodium chloride and 10-20 mg / L of sodium chloride. The invention relates to a neisseria gonorrhoeae culture medium, which is characterized in that neisseria gonorrhoeae in a sample can be directly separated and identified by adopting the culture medium, and a separated bacterial colony can be directly used for a drug sensitive test. The neisseria gonorrhoeae can be directly separated and identified by adopting the neisseria gonorrhoeae culture medium for the drug sensitive test of neisseria gonorrhoeae in the sample.

The invention provides a primer and a probe for detecting related pathogens of vaginitis through multiple RPA (recombinase polymerase amplification)-lateral flow immunochromatography. The primer comprises a neisseria gonorrhoeae porA gene primer pair, a gardnerella vaginalis 16S rRNA (ribosomal Ribonucleic Acid) gene primer pair, a candida albicans ITS2 gene primer pair, a trichomonas vaginalis actin gene primer pair and a ureaplasma urealyticum Urease gene primer pair. The probes comprise a gold nanoparticle binding probe, a quality control line capture probe and capture probes corresponding to the five genes. The invention also provides application of the primer and the probe in preparation of vaginitis-related pathogen detection products, and also provides a corresponding detection kit and method. According to the invention, the rapid and accurate detection of five common vaginitis pathogens is realized through the RPA-lateral flow immunochromatography technology, and the kit is suitable for rapid, early and convenient diagnosis of vaginitis patients.

The invention discloses genetically modified neisseria gonorrhoeae and a neisseria gonorrhoeae outer membrane vesicle vaccine, and a gene modification mode is that at least one of a coding gene of PorB1a protein and a coding gene of PorB1b protein is subjected to gene mutation, so that the capability of inducing mitochondrial autophagy is reduced or weakened. According to the present invention, the induction of the mitochondrial autophagy pathway is effectively prevented by precisely mutating the key amino acids (PorB1a-K117Q / K171Q or PorB1b-K117Q / K170Q) at the 117 site and the 171 / 170th site of the PorB protein; the protective efficacy of the neisseria gonorrhoeae OMVs vaccine is improved compared with that of the neisseria gonorrhoeae OMVs vaccine prepared from wild bacteria, and a new treatment means is provided for gonorrhoeae prevention and treatment.

Described herein are vaccine compositions and methods of selecting an antigen or fragment thereof for the preparation of a vaccine composition. The methods and vaccine compositions described herein are based, in part, on the discovery that certain polypeptides not previously identified or considered for potential use as antigens from pathogenic microorganisms (e.g., N. gonorrhoeae) can provoke an immune response in a subject. The methods of identifying and selecting the antigens described herein rely, in part, on approaches that identify polypeptides (e.g., hypothetical proteins) predicted to be immunogenic.

The invention relates to a method for detecting the presence of at least two pathogens in a sample, wherein additionally subtypes and / or variant-derived properties such as treatment susceptibility are determined. The method may be a polymerase chain reaction and may be facilitated by a cartridge and dried reagents. The pathogens may be bacterial pathogens such as Chlamydia trachomatis and Neisseria gonorrhoeae. The invention further relates to a cartridge and / or a cartridge reader for performing the method of the invention.

This invention provides a composition for detecting genital tract pathogens, its preparation method, and its application, belonging to the field of nucleic acid or microbial assays or tests. The composition provided by this invention includes a forward primer, a reverse primer, and a probe targeting seven genital tract pathogens. The forward and reverse primers are used to amplify the target DNA. A blocking group is added between the i-th nucleotide and the (i+1)-th nucleotide from the 3' end of the reverse primer, where 4 ≤ i ≤ 8. The probe is labeled with a fluorescent group and a second quenching group at both ends, and a first quenching group in the middle. A portion of the probe's sequence is identical to a portion of the reverse primer's sequence. The composition provided by this invention enables multiplex qualitative detection of seven genital tract pathogens: Neisseria gonorrhoeae, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma microsporum, Mycoplasma hominis, Mycoplasma genitalium, and herpes simplex virus type 2.

The invention provides application of tripterine or a derivative thereof in preparation of a product for inhibiting neisseria gonorrhoeae, and relates to the technical field of biology and bacteriostasis. The invention particularly relates to application of tripterine or a derivative thereof in preparation of a neisseria gonorrhoeae inhibitor; or (II) application in preparation of a medicine for preventing, relieving and / or treating neisseria gonorrhoeae infection; the invention relates to a medicine for treating or preventing infection and / or complications caused by neisseria gonorrhoeae and a method for inhibiting or preventing growth of neisseria gonorrhoeae.

The present invention discloses series of compounds as a new antibiotic for the treatment of a subject with various infections, including infections caused by Neisseria gonorrhoeae. In particular, those compounds comprise α-methylene and α-aminomethyl lactones, lactams, iminolactones, and iminolactams, thiolactones, thionolactones, thiolactams, and thionolactams. Pharmaceutical compositions and methods for treating those infections are within the scope of this invention.

The invention belongs to the technical field of biology, and provides a chlamydia trachomatis and gonococci double-target immunochromatography detection method which comprises the following steps: introducing a dibenzocyclooctyne group to the tail end of lipopolysaccharide of the chlamydia trachomatis, introducing a trans-cyclooctene group into outer membrane protein of gonococci, and detecting the chlamydia trachomatis and gonococci double-target immunochromatography. In the chromatographic detection process, the antibody can form two non-interfering detection channels with an anti-lipopolysaccharide antibody containing an azide group and an anti-outer membrane protein antibody containing a tetrazine group. Through the improvement, the problem that a high-concentration antigen occupies a binding site or interferes with a chromatography process due to nonspecificity can be avoided, and high specificity and high sensitivity of detection are ensured.

This invention relates to the field of biomedical detection technology, specifically to plasma circulating microbial biomarkers for early screening of gastric cancer and their applications. The plasma circulating microbial biomarkers include: *Ralstonia solanacearum*, *Staphylococcus aureus*, *Alternaria metachromatica*, *Porphyromonas gingivalis*, *Lactobacillus reuteri*, *Rhodococcus erythropolis*, *Akkermansia muciniphila*, *Lactobacillus gasseri*, *Bifidobacterium bifidum*, and *Neisseria gonorrhoeae*. This invention screens and, for the first time, combines 10 specific microbial biomarkers with Low Pass technology. WGS technology can achieve detection results at low depths, significantly reducing screening costs while ensuring detection sensitivity, and providing a brand-new solution for early gastric cancer screening.

The application provides a method for detecting 19 Neisseria gonorrhoeae drug resistance site mutations. The method uses multiplex PCR-mass spectrometry to detect 19 Neisseria gonorrhoeae drug resistance site mutations. The detection method comprises the following steps: 1) designing primers for different drug resistance sites; 2) multiplex PCR amplification reaction; 3) shrimp alkaline phosphatase treatment; 4) single base extension reaction; 5) resin desalting purification; and 6) mass spectrometry detection.

Immunogenic and vaccine compositions containing a Neisseria gonorrhoeae lipooligosaccharide (LOS), or a fragment thereof, are provided. The LOS may be conjugated to a carrier such as a carrier protein, virus-like particle (VLP), liposome, inorganic gold particle, dendrimer, outer membrane vesicle (OMV), generalized modules for membrane antigens (GMMA), and protein nanocages. Methods of protecting or treating a subject from Neisseria gonorrhoeae infection and methods of manufacturing the compositions are also provided.

Isolated antigen binding polypeptides having a heavy chain variable region and / or light chain variable region that specifically binds to a lipo-oligosaccharide (LOS) epitope of Neisseria gonorrhoeae as well as antibodies and antigen binding antibody fragments containing the heavy chain variable region and / or the light chain variable region that bind to a lipo-oligosaccharide (LOS) epitope of Neisseria gonorrhoeae are provided. Pharmaceutical compositions and kits comprising the isolated antigen binding polypeptide and antibodies or antigen binding antibody fragments thereof comprising the antigen binding polypeptide are also provided, along with methods of treating an infection caused by Neisseria gonorrhoeae and methods of making the polypeptides, antibodies and antigen-binding antibody fragments.

A method of detecting the presence of Neisseria gonorrhoeae in a sample. The method involves detecting a first target sequence taken from the NGO1642 gene and / or a second target sequence taken from the NGO1012 gene. The method may involve a step of amplifying the target sequence and may involve hybridising the target sequence to a nucleic acid probe and identifying hybridisation. The method may involve simultaneous detection of other target sequences, e.g., from other pathogens.

Described in several example embodiments herein are compositions and methods to treat and / or prevent infection with a Neisseria species (sp) infection and / or a disease or disorder caused by a Neisseria species (sp) or a symptom thereof. In some embodiments, the Neisseria sp. is Neisseria gonorrhoeae or N. meningitidis.

In some aspects, the disclosure relates to compositions of peptide mimics useful in the treatment of Neisseria gonorrhoeae (N. gonorrhoeae). In some embodiments, the peptide mimics are multi-antigenic molecules of a conserved gonococcal lipo-oligosaccharaide (LOS) epitope. In some aspects, the disclosure relates to methods of making peptide mimics for the treatment of N. gonorrhoeae. In some aspects, the disclosure relates to methods of using peptide mimics for the treatment of N. gonorrhoeae.

The present invention relates to compositions and methods for preventing and / or treating bacterial disease (e.g., disease caused by Neisseria sp. such as Neisseria gonorrhoeae or Neisseria meningitidis). In particular, the present invention provides compositions comprising an effective amount of a nucleic acid, wherein such compositions are capable of killing or inhibiting the growth of a Neisseria sp.

The invention relates to a composition comprising OMVs obtained from a modified Neisseria gonorrhoeae strain expressing a PorB variant, methods for preparing said composition, and its uses including vaccines.

The invention relates to an essential oil composition extracted from Chinese herbal medicines, which has a killing effect on neisseria gonorrhoeae and is suitable for treating urogenital system infection and pharyngolaryngitis. The liquid medicine is prepared from the following Chinese herbal medicine essential oil in parts by weight: 6-40 parts of peppermint essential oil, 12-31 parts of oregano essential oil, 14-80 parts of eucalyptus oil, 10-65 parts of chamomile essential oil, 15-75 parts of tea tree essential oil, 17-80 parts of balm essential oil and 9-27 parts of thyme essential oil. The invention relates to a Chinese herbal medicine powerful bactericidal composition with fragrant smell, and the bactericidal rate gt of neisseria gonorrhoeae; the yield is 99.97%. The traditional Chinese medicine composition is safe to use, has no irritation to skin mucous membrane tissues, also has a lubricating effect, and creates another new chapter in China and even in the world in the technical field of medicines for treating infectious diseases by utilizing the safe and powerful bactericidal and antibacterial characteristics of Chinese herbal medicines. The method can be widely applied to the fields of medicines, health care products, antibacterial and bacteriostatic hygienic products and the like.

The application provides application of sorafenib in preparation of a product for inhibiting Neisseria gonorrhoeae, and relates to the technical field of biology and bacteriostasis. The application comprises application of sorafenib or a derivative thereof in (I) preparation of a Neisseria gonorrhoeae inhibitor; or (II) preparation of a medicine for preventing, relieving and / or treating Neisseria gonorrhoeae; a medicine for treating or preventing infection and / or complications caused by Neisseria gonorrhoeae; a method for inhibiting or preventing growth of Neisseria gonorrhoeae; and the application provides a new potential medicine selection for treating drug-resistant gonorrhea, and has important clinical application value.

The present application generally relates to compounds which are inhibitors of Neisseria gonorrhoeae. Compounds, pharmaceutical compositions and use thereof are within the scope of this disclosure.

Disclosed herein are compositions for generating a synthetic antibody or synthetic multivalent antibody in a subject. Also disclosed are methods for generating a synthetic antibody or synthetic multivalent antibody in a subject by administering a composition including one or more recombinant nucleic acid sequence that encodes a synthetic antibody or synthetic multivalent antibody to the subject. The disclosure also provides a compositions and methods of preventing and / or treating a Neisseria gonorrhoeae infection in a subject using said synthetic antibody or synthetic multivalent antibody.